See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Vatican
Ukraine War
Volodymyr Zelenskyy
Olaf Scholz
Donald Trump
Elon Musk
Israel-Hamas Conflict
Vladimir Putin
Premier League
Baseball
Tennis
Published • loading... • Updated

Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - Third Harmonic Bio (NASDAQ:THRD)

Summary by Benzinga
Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options.

1 Articles

All
Left
Center
1
Right
BenzingaBenzinga

Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - Third Harmonic Bio (NASDAQ:THRD)

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options.

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Wednesday, February 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

South San Francisco

South San Francisco

News
For You
Search
BlindspotLocal